Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy.
Adipose Tissue
/ diagnostic imaging
Adult
Disease Progression
Female
Humans
Inflammation
/ diagnostic imaging
Leg
Longitudinal Studies
Magnetic Resonance Imaging
Male
Middle Aged
Muscle Strength
Muscle Strength Dynamometer
Muscle, Skeletal
/ diagnostic imaging
Muscular Dystrophy, Facioscapulohumeral
/ diagnostic imaging
Thigh
Walk Test
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
21
03
2019
accepted:
05
03
2020
pubmed:
3
7
2020
medline:
27
10
2020
entrez:
3
7
2020
Statut:
ppublish
Résumé
We followed up patients with facioscapulohumeral muscular dystrophy (FSHD) with sequential examinations over 2 years to investigate whether inflammatory lesions always precede fat replacement, if inflammation can be resolved without muscle degeneration, and if inflammatory lesions in muscle are always followed by fat replacement. In this longitudinal study of 10 sequential MRI assessments over 2.5 years, we included 10 patients with FSHD. We used MRI with short TI inversion recovery to identify regions of interest (ROIs) with hyperintensities indicating muscle inflammation. Muscle T2 relaxation time mapping was used as a quantitative marker of muscle inflammation. Dixon sequences quantified muscle fat replacement. Ten healthy controls were examined with a magnetic resonance scan once for determination of normal values of T2 relaxation time. We identified 68 ROIs with T2 elevation in the patients with FSHD. New ROIs with T2 elevation arising during the study had muscle fat content of 6.4% to 33.0% (n = 8) and 47.0% to 78.0% lesions that resolved (n = 6). ROIs with T2 elevation had a higher increase in muscle fat content from visits 1 to 10 (7.9 ± 7.9%) compared to ROIs with normal muscle T2 relaxation times (1.7 ± 2.6%; Our results suggest that muscle inflammation starts in mildly affected muscles in FSHD, is related to a faster muscle degradation, and continues until the muscles are completely fat replaced. NCT02159612.
Identifiants
pubmed: 32611642
pii: WNL.0000000000010155
doi: 10.1212/WNL.0000000000010155
doi:
Banques de données
ClinicalTrials.gov
['NCT02159612']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1211-e1221Informations de copyright
© 2020 American Academy of Neurology.